Host endosomal entry / trafficking
MoreNasal & Oral Sprays / Rinses
MoreHost targets and pathways
MoreInflammatory and immune modulation
MoreOxidative stress and cytoprotection
MoreReplication inhibition (target unresolved)
MorePleiotropic modulation
MoreAttachment / entry inhibition
MoreNutrients and microbiome support
MoreIL-6 / IL-6R blockade
MorePhysical and extracorporeal interventions
MoreNatural products and extracts
MoreUnconfirmed antiviral rationale
MoreLifestyle, behaviors, and exposure prevention
MoreOther complication management
MoreHost pyrimidine synthesis
MoreDirect viral inactivation
MoreEndothelial / vascular protection
MoreDirect respiratory tract treatments
MoreOther antibodies, proteins, peptides, cells, and RNA therapies
MoreSecondary infection and coinfection management
More
114 patient ramipril late treatment RCT: 144% higher mortality (p=1), 289% higher ventilation (p=1), 289% higher ICU admission (p=1), and 144% lower hospital discharge (p=1).
RCT 114 non-critically ill COVID-19 patients in the USA showing no significant differences with ramipril treatment.
Aug 2023, Advances in Therapy, https://link.springer.com/10.1007/s12325-023-02618-7, https://c19p.org/huang18
